Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TST001 + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Transcenta
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy comprised of TST001 (osemitamab), gemcitabine, and nab-paclitaxel. **TST001** is a humanized IgG1 monoclonal antibody targeting claudin 18.2 (CLDN18.2), a tight junction protein aberrantly expressed in various gastrointestinal malignancies, notably gastric/gastroesophageal junction (G/GEJ) and pancreatic cancers. It exerts anti-tumor effects primarily through antibody-dependent cell-mediated cytotoxicity (ADCC), with enhanced NK cell activation due to reduced fucose content[5][1]. **Gemcitabine** is a nucleoside analog antimetabolite interfering with DNA synthesis and repair, and **nab-paclitaxel** (albumin-bound paclitaxel) is a microtubule inhibitor formulated to improve paclitaxel delivery and tolerability[2][6]. This triple combination is under investigation for HER2-negative, unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, and pancreatic cancers.
- Brand names
- Osemitamab
- Other names
- TST001 + gemcitabine + nab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))Claudin 18.2DNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on TST001 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TST001 + gemcitabine + nab-paclitaxel.